Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

PENTASA SUPPOSITORIES 1 G [SIN07740P]

Active ingredients: PENTASA SUPPOSITORIES 1 G

View product's general information
Last updated 24 April 2026

Product Info

PENTASA SUPPOSITORIES 1 G

[SIN07740P]

Product information

Active Ingredient and Strength

MESALAZINE - 1 G

Dosage Form

SUPPOSITORY

Manufacturer and Country

FERRING INTERNATIONAL CENTER SA (PRIMARY AND SECONDARY PACKAGER) - SWITZERLAND
FERRING INTERNATIONAL CENTER SA - SWITZERLAND

Registration Number

SIN07740P

Licence Holder

FERRING PHARMACEUTICALS PRIVATE LIMITED

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

A07EC02

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

THERAPEUTIC INDICATIONS
Treatment of ulcerative proctitis.

Dosing

POSOLOGY AND METHOD OF ADMINISTRATION
Posology:
1 suppository 1–2 times daily.

Paediatric population:
There is little experience and only limited documentation for an effect in children.

Method of administration:

  1. A visit to the toilet is recommended before inserting a suppository.

  2. Open the foil bag at the tear mark.

  3. The suppository is inserted in the rectum until resistance is felt and disappeared again.

  4. In order to facilitate the administration, the suppository can be moistured with water or moisture cream.

  5. If the suppository is discharged within the first 10 minutes, another can be inserted.

Contraindications

CONTRAINDICATIONS
Hypersensitivity to mesalazine, any of the components of the product, or salicylates.
Severe liver and/or renal impairment.